Among patients with hypereosinophilia, a myeloproliferative variant is recognized. In many
of these patients a diagnosis of eosinophilic leukemia can be made. The molecular …

Eosinophilia is typically secondary, that is, reactive, in nature and is associated with a wide
variety of neoplastic and non‐neoplastic disorders. Clonal eosinophilia is also seen in a …

The 2008 World Health Organization (WHO) classi-fication of tumors of hematopoietic and
lymphoid tissues introduced a new category for myeloid and lymphoid neoplasms with …

Abstract Purpose: Molecular characterization of Philadelphia chromosome–negative (Ph−)
chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a …

Objective Patients receiving oral chemotherapies face treatment interruptions if they require
placement of an enteral tube for nutrition, potentially leading to adverse outcomes in cancer …

Myeloid and lymphoid neoplasms with eosinophilia and PDGFRA rearrangements are
recognized as a distinct entity within the section of “Myeloid/Lymphoid neoplasms with …

Session 2 of the 2007 Workshop of the Society for Hematopathology/European Association
for Haematopathology was focused on Philadelphia chromosome–negative chronic …

Zusammenfassung Klinisch weisen das Churg-Strauss-Syndrom und das hypereosinophile
Syndrom insbesondere in den frühen Krankheitsstadien zahlreiche Gemeinsamkeiten auf …

The myeloid and lymphoid neoplasms with eosinophilia and PDGFRA gene rearrangements
usually show a good response to Imatinib and are typically associated with a normal …

Eosinophilic and mast cell disorders are uncommon hematologic entities, but they can carry
significant morbidity and lead to devastating end-organ sequelae. In the past ten years …